Conference Call with Indoco Remedies Ltd. Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Indoco Remedies announced Q4FY23 & FY23 results: Q4FY23: During Q4FY23, revenues grew by 6.9% at Rs 428.0 crore, as against Rs 400.3 crore in Q4FY22 EBIDTA to net sales for Q4FY23 is 15.0% at Rs 64.2 crore, compared to 20.1% at Rs 80.5 crore in Q4FY22 For Q4FY23, the Profit After Tax is at Rs 25.4 crore, compared to Rs 40.4 crore in Q4FY22 Profit After Tax with other comprehensive income is at Rs 29.7 crore, compared to Rs 35.6 crore in Q4FY22 FY23: For FY23, the revenues grew by 9.0% at Rs 1,638.1 crore, as against Rs 1,502.7 crore in FY22 EBIDTA to net sales for FY23 is 17.4% at Rs 284.9 crore, compared to 21.8% at Rs 327.0 crore in FY22 For FY23, the Profit After Tax is at Rs 141.4 crore, compared to Rs 154.5 crore in FY22 Profit After Tax with other comprehensive income is at Rs 142.8 crore, compared to Rs 149.2 crore in FY22 Commenting on the results, Aditi Panandikar, Managing Director, Indoco Remedies said, “Our performance this year is a function of a predictable performance of India business, free of COVID impact, accompanied by a good performance of Export business”. Result PDF
Conference Call with Indoco Remedies Management and Analysts on Q3FY23 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceutical firm Indoco Remedies announced Q3FY23 results: Q3FY23 vs Q3FY22: During the Q3FY23, revenues of Indoco Remedies grew by 17.8% at Rs 410.6 crore, as against Rs 348.6 crore, in the same quarter last year. EBIDTA to net sales for the quarter is 15.0% at Rs 61.7 crore, compared to 21.1% at Rs 73.4 crore, in the same quarter last year. EBIDTA to net sales without the impact of other operating income stands at 17.9 %. For the quarter, the profit after tax is Rs 27.9 crore. 9MFY23 vs 9MFY22: The revenues grew by 9.8% at Rs 1,210.1 crore, as against Rs 1,102.4 crore, in the same period last year. EBIDTA to net sales for the period is 18.2% at Rs 220.7 crore, compared to 22.4% at Rs 246.5 crore, in the same period last year. During the period, the profit after tax is Rs 116 crore. Commenting on the third quarter FY23 results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd. said, “A good performance in Domestic business and an excellent growth in Export business has allowed us to post good results this quarter”. Result PDF